1.
Pediatr Blood Cancer
; 68(4): e28818, 2021 04.
Article
in English
| MEDLINE
| ID: mdl-33211391
Subject(s)
Antineoplastic Agents/therapeutic use , Bortezomib/therapeutic use , Glucocorticoids/therapeutic use , Plasma Exchange , Purpura, Thrombocytopenic, Idiopathic/therapy , Rituximab/therapeutic use , Child , Child, Preschool , Female , Humans , Purpura, Thrombocytopenic, Idiopathic/drug therapy
2.
Pediatr Blood Cancer
; 66(6): e27704, 2019 06.
Article
in English
| MEDLINE
| ID: mdl-30854783
ABSTRACT
We retrospectively analyzed sequential therapy with romiplostim and eltrombopag in 23 children with immune thrombocytopenia: switching from romiplostim to eltrombopag (10 patients) or vice versa (13 patients). The median age of patients at enrollment in the study was 5.6 years (2-15 years). Switching from romiplostim to eltrombopag was effective in eight (80%) patients, whereas switching from eltrombopag to romiplostim was effective in eight (62%) patients. The response rate was similar in patients failing the first thrombopoietin receptor agonist and those who had previous response. To date, all responders continue to maintain platelets over 50 × 109 /L at 13-39 months after switching.